NOVACYT SIGNS $3.0M DIAGNOSTICS SUPPLY AGREEMENT WITH GENESIS DIAGNOSTICS

PrimerDesign Genesis Diagnostics ENG

Paris, France and Camberley, UK – 27th November 2018 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces its molecular testing division, Primerdesign Ltd. (Primerdesign), has signed an exclusive supply agreement worth a minimum of $3 million with Genesis Diagnostics, a US-based full service diagnostic laboratory that offers clinical diagnostic testing, oral fluid drug testing and services focused on drug monitoring, substance abuse programmes, infectious disease, and personalised medicine.